PubRank

Marc Piechaczyk

Author PubWeight™ 36.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CNF1 exploits the ubiquitin-proteasome machinery to restrict Rho GTPase activation for bacterial host cell invasion. Cell 2002 2.77
2 The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem 2003 2.02
3 Ubiquitin-independent degradation of proteins by the proteasome. Biochim Biophys Acta 2008 1.69
4 Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 2005 1.55
5 SUMO under stress. Biochem Soc Trans 2008 1.47
6 SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J Cell Biol 2004 1.24
7 Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol 2007 1.16
8 c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo. Mol Cell Biol 2003 1.06
9 The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene 2003 1.04
10 SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol 2008 1.03
11 Heterodimerization with Jun family members regulates c-Fos nucleocytoplasmic traffic. J Biol Chem 2007 0.99
12 Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution. J Biol Chem 2010 0.96
13 Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells. Virology 2005 0.96
14 JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis. Mol Cell Biol 2008 0.93
15 A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog 2010 0.92
16 A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol Biol Cell 2008 0.91
17 Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer? Biochimie 2007 0.91
18 Efficient gene transfer into spleen cells of newborn mice by a replication-competent retroviral vector. Virology 2002 0.84
19 An NF-kappaB-dependent role for JunB in the induction of proinflammatory cytokines in LPS-activated bone marrow-derived dendritic cells. PLoS One 2010 0.84
20 High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther 2002 0.84
21 Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther 2004 0.82
22 Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood 2012 0.82
23 Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol 2005 0.82
24 Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor. J Virol 2003 0.81
25 Multiple degradation pathways for Fos family proteins. Ann N Y Acad Sci 2002 0.80
26 Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol 2010 0.80
27 Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol 2007 0.80
28 Fos family protein degradation by the proteasome. Biochem Soc Trans 2008 0.80
29 Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy? Crit Rev Oncol Hematol 2005 0.79
30 The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol J 2006 0.79
31 Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy. J Virol 2006 0.79
32 The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells. Virus Res 2002 0.79
33 In vivo infection of mice by replication-competent MLV-based retroviral vectors. Methods Mol Med 2003 0.78
34 Skin as a potential organ for ectopic monoclonal antibody production. J Invest Dermatol 2002 0.78
35 Monoclonal antibody-based genetic immunotherapy. Curr Gene Ther 2004 0.77
36 Chromatin loop organization of the junb locus in mouse dendritic cells. Nucleic Acids Res 2013 0.76
37 Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses. Biochem Pharmacol 2002 0.75
38 [Proteasomal degradation: from addressing of substrates to therapeutical perspectives]. Med Sci (Paris) 2005 0.75
39 [Vaccine-like effects of antiviral monoclonal antibodies: a novel therapeutic perspective?]. Med Sci (Paris) 2013 0.75